Vector BioMed (VBM), a biomanufacturing company specializing in lentiviral vectors, entered into an agreement with the California Institute for Regenerative Medicine (CIRM) to be a lentiviral vector manufacturer within CIRM’s Industry Alliance Program (IAP). With $5.5 billion in funding from the state of California, CIRM is involved in the development and funding of regenerative medicine clinical trials focused on cell-based and gene therapies.

VBM helps design and manufacture high-quality preclinical and GMP lentiviral vectors at a speed, price, and scale for its clients.  As a preferred lentiviral vector manufacturing partner for CIRM, VBM will assist CIRM investigators in accelerating development to the clinic leveraging the VBM teams’ experience in design and manufacture of preclinical and GMP-grade lentiviral vectors.   

“We are very pleased to serve as a preferred lentiviral vector manufacturing partner for CIRM and provide investigators with high-quality lentiviral vectors using the extensive experience of the VBM team,” said Boro Dropulić, CEO of Vector BioMed. “CIRM and its members are at the forefront of advancing the next generation of cell and gene therapies for cancer and other difficult-to-treat diseases. Essential to these technologies is rapid access to custom GMP lentiviral vectors.  With this agreement, Vector BioMed will help CIRM-funded investigators rapidly translate their concepts into the clinic.”

“The acceleration of CAR-T cell therapy in cancer and hematopoietic stem cells for genetic diseases has created significant demand for custom lentiviral vectors at CIRM and among our IAP partners,” said Shyam Patel, director of business Development at CIRM.  “We welcome the opportunity to partner with Vector BioMed and benefit from the company’s unique lentiviral vector solutions, including algorithm-optimized vectors that enable superior vector titer and function, as well as a platform serum-free suspension vector manufacturing process that is suitable for rapid clinical development.”